Document Detail


Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.
MedLine Citation:
PMID:  22441386     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Current oral cholera vaccines induce lower protective efficacy and shorter duration of protection against cholera than wild-type infection provides, and this difference is most pronounced in young children. Despite this, there are limited data comparing immune responses in children following wild-type disease versus vaccination, especially with regard to memory responses associated with long-term immunity. Here, we report a comparison of immune responses in young children (2 to 5 years of age; n = 20) and older children (6 to 17 years of age; n = 20) given two doses of an oral killed cholera vaccine containing recombinant cholera toxin B subunit (CtxB) 14 days apart and compare these responses to those induced in similarly aged children recovering from infection with Vibrio cholerae O1 Ogawa in Bangladesh. We found that the two vaccine groups had comparable vibriocidal and lipopolysaccharide (LPS)-specific plasma antibody responses. Vaccinees developed lower levels of IgG memory B cell (MBC) responses against CtxB but no significant MBC responses against LPS. In contrast, children recovering from natural cholera infection developed prominent LPS IgG and IgA MBC responses, as well as CtxB IgG MBC responses. Plasma LPS IgG, IgA, and IgM responses, as well as vibriocidal responses, were also significantly higher in children following disease than after vaccination. Our findings suggest that acute and memory immune responses following oral cholera vaccination in children are significantly lower than those observed following wild-type disease, especially responses targeting LPS. These findings may explain, in part, the lower efficacy of oral cholera vaccination in children.
Authors:
Daniel T Leung; Mohammad Arif Rahman; M Mohasin; Sweta M Patel; Amena Aktar; Farhana Khanam; Taher Uddin; M Asrafuzzaman Riyadh; Amit Saha; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Richelle Charles; Regina LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Related Documents :
22521906 - Malaria vaccine development: persistent challenges.
22590466 - Host defense pathways against fungi: the basis for vaccines and immunotherapy.
22442716 - Therapeutic dna vaccine induces broad t cell responses in the gut and sustained protect...
22461526 - A novel tuberculosis dna vaccine in an hiv-1 p24 protein backbone confers protection ag...
20437376 - Immune response and protective efficacy in sheep immunised with hydroxylamine-inactivat...
3295846 - Listeriosis: a cause of non-immune hydrops fetalis.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, American Recovery and Reinvestment Act; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-03-21
Journal Detail:
Title:  Clinical and vaccine immunology : CVI     Volume:  19     ISSN:  1556-679X     ISO Abbreviation:  Clin. Vaccine Immunol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-27     Completed Date:  2012-08-15     Revised Date:  2014-04-25    
Medline Journal Info:
Nlm Unique ID:  101252125     Medline TA:  Clin Vaccine Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  690-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Age Factors
Antibodies, Bacterial / blood
B-Lymphocytes / immunology*
Bangladesh
Blood Bactericidal Activity
Child
Child, Preschool
Cholera / immunology*
Cholera Vaccines / administration & dosage,  immunology*
Female
Humans
Immunoglobulin A / blood
Immunoglobulin G / blood
Immunologic Memory*
Male
Vaccination / methods*
Vaccines, Inactivated / administration & dosage,  immunology
Vibrio cholerae O1 / immunology*
Grant Support
ID/Acronym/Agency:
D43 TW005572/TW/FIC NIH HHS; K01 TW07409/TW/FIC NIH HHS; K08 AI089721/AI/NIAID NIH HHS; R03 AI063079/AI/NIAID NIH HHS; R24 TW007988/TW/FIC NIH HHS; TW005572/TW/FIC NIH HHS; TW05572/TW/FIC NIH HHS; TW07144/TW/FIC NIH HHS; U01 AI058935/AI/NIAID NIH HHS; U01 AI058935/AI/NIAID NIH HHS; U01 AI077883/AI/NIAID NIH HHS; U01 AI077883/AI/NIAID NIH HHS; //Howard Hughes Medical Institute
Chemical
Reg. No./Substance:
0/Antibodies, Bacterial; 0/Cholera Vaccines; 0/Immunoglobulin A; 0/Immunoglobulin G; 0/Vaccines, Inactivated
Comments/Corrections
Erratum In:
Clin Vaccine Immunol. 2012 Aug;19(8):1337

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Microbiological challenges in the diagnosis of chronic Q fever.
Next Document:  Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated t...